leniolisib: Clinical Trials

5 trials of leniolisib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed, 1 terminated, 1 unknown. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Active not recruiting 2, Completed 1, Terminated 1, Unknown 1
Phase 22Completed 1, Terminated 1

Follow leniolisib: new trials by email Literature Review of leniolisib trials Research Report on leniolisib

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pediatric Patients Aged 1 to 6 Years With APDS
Leniolisib - APDS
Phase 3Active not recruitingPharming Technologies B.V.162023-08-302026-06-15
An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
Leniolisib - APDS Gene Mutation
Phase 3UnknownPharming Technologies B.V.32023-08-032024-02-08
Pediatric Patients Aged 4 to 11 Years With APDS
Leniolisib - APDS
Phase 3Active not recruitingPharming Technologies B.V.152023-02-012026-05-06
Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
CDZ173 - Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Phase 2 / Phase 3TerminatedPharming Technologies B.V.372016-09-082026-03-30
Study of Efficacy of CDZ173 in Patients With APDS/PASLI
CDZ173, Placebo - Common Variable Immunodeficiency (CVID), APDS / PASLI
Phase 2 / Phase 3CompletedNovartis Pharmaceuticals372015-08-242022-08-10

Conditions studied

Activated PI3K-delta Syndrome (2)  ·  Common Variable Immunodeficiency (1)  ·  Immunologic Deficiency Syndromes (1)  ·  Lymphadenopathy (1)

Sponsors

Pharming Technologies B.V. (4)  ·  Novartis Pharmaceuticals (1)

Countries

United States (4)  ·  Japan (3)  ·  Belarus (2)  ·  Czechia (2)  ·  Germany (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Russia (2)  ·  United Kingdom (2)  ·  France (1)  ·  Ireland (1)  ·  Portugal (1)  ·  Spain (1)

Top investigators

Hirokazu Kanegane, Prof. (1)  ·  Koneti V Rao, MD (1)  ·  Virgil Dalm, MD (1)

Results publications

PMID 28972011, PMID 36399712, PMID 37797893, PMID 38593221, PMID 41091701

NIH funding

2014 (1), 2016 (1)